Immunome (IMNM) News Today $6.95 -1.20 (-14.72%) Closing price 04:00 PM EasternExtended Trading$7.02 +0.08 (+1.08%) As of 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Immunome (NASDAQ:IMNM) Reaches New 52-Week Low - Should You Sell?Immunome (NASDAQ:IMNM) Reaches New 12-Month Low - Time to Sell?March 25 at 4:30 AM | marketbeat.comImmunome (IMNM) to Release Quarterly Earnings on ThursdayMarch 25 at 2:21 AM | americanbankingnews.comWedbush Comments on Immunome's Q1 Earnings (NASDAQ:IMNM)March 25 at 1:13 AM | americanbankingnews.comWedbush Has Positive Estimate for Immunome Q1 EarningsImmunome, Inc. (NASDAQ:IMNM - Free Report) - Investment analysts at Wedbush raised their Q1 2025 earnings estimates for Immunome in a research report issued on Wednesday, March 19th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.51) per share for the quarter, up fromMarch 24 at 1:12 AM | marketbeat.comImmunome (NASDAQ:IMNM) Price Target Cut to $25.00 by Analysts at GuggenheimMarch 23 at 3:07 AM | americanbankingnews.comImmunome (NASDAQ:IMNM) Receives Overweight Rating from StephensMarch 22 at 3:21 AM | americanbankingnews.comWedbush Keeps Their Buy Rating on Immunome (IMNM)March 21, 2025 | markets.businessinsider.comImmunome (IMNM) Receives a Buy from Piper SandlerMarch 21, 2025 | markets.businessinsider.comImmunome (NASDAQ:IMNM) Receives "Outperform" Rating from WedbushWedbush restated an "outperform" rating and set a $33.00 target price on shares of Immunome in a research report on Thursday.March 21, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Given "Overweight" Rating at StephensStephens reaffirmed an "overweight" rating and set a $30.00 price objective on shares of Immunome in a research note on Thursday.March 21, 2025 | marketbeat.comImmunome price target lowered to $25 from $35 at GuggenheimMarch 21, 2025 | markets.businessinsider.comGuggenheim Has Lowered Expectations for Immunome (NASDAQ:IMNM) Stock PriceGuggenheim lowered their target price on Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a report on Thursday.March 21, 2025 | marketbeat.comImmunome’s 2024 Financial Results and Pipeline ProgressMarch 21, 2025 | tipranks.comImmunome (NASDAQ:IMNM) Issues Quarterly Earnings Results, Misses Expectations By $0.16 EPSImmunome (NASDAQ:IMNM - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%.March 20, 2025 | marketbeat.comImmunome reports FY24 revenue $9.04M, consensus $9.41MMarch 20, 2025 | markets.businessinsider.comImmunome (NASDAQ:IMNM) Hits New 52-Week Low - Here's What HappenedImmunome (NASDAQ:IMNM) Hits New 12-Month Low - Here's What HappenedMarch 20, 2025 | marketbeat.comImmunome (IMNM) Expected to Announce Quarterly Earnings on ThursdayImmunome (NASDAQ:IMNM) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comWith 59% ownership of the shares, Immunome, Inc. (NASDAQ:IMNM) is heavily dominated by institutional ownersMarch 17, 2025 | finance.yahoo.comImmunome, Inc. (NASDAQ:IMNM) Receives $27.17 Average Price Target from AnalystsMarch 16, 2025 | americanbankingnews.comLifesci Capital Estimates Immunome FY2024 EarningsImmunome, Inc. (NASDAQ:IMNM - Free Report) - Equities research analysts at Lifesci Capital issued their FY2024 EPS estimates for shares of Immunome in a note issued to investors on Tuesday, March 11th. Lifesci Capital analyst C. Zhu forecasts that the company will earn ($1.83) per share for the yMarch 15, 2025 | marketbeat.comWhat is Lifesci Capital's Estimate for Immunome Q1 Earnings?March 15, 2025 | americanbankingnews.comLifesci Capital Predicts Immunome FY2024 EarningsMarch 15, 2025 | americanbankingnews.comQ1 Earnings Estimate for Immunome Issued By Lifesci CapitalImmunome, Inc. (NASDAQ:IMNM - Free Report) - Stock analysts at Lifesci Capital issued their Q1 2025 EPS estimates for shares of Immunome in a report issued on Tuesday, March 11th. Lifesci Capital analyst C. Zhu forecasts that the company will earn ($0.61) per share for the quarter. Lifesci CapitaMarch 14, 2025 | marketbeat.comLifeSci Capital Initiates Coverage of Immunome (IMNM) with Outperform RecommendationMarch 12, 2025 | msn.comImmunome, Inc. (NASDAQ:IMNM) Given Consensus Recommendation of "Buy" by BrokeragesImmunome, Inc. (NASDAQ:IMNM - Get Free Report) has earned a consensus recommendation of "Buy" from the six analysts that are presently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month target price among brokeragesMarch 12, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Coverage Initiated by Analysts at Lifesci CapitalLifesci Capital started coverage on shares of Immunome in a report on Tuesday. They set an "outperform" rating and a $20.00 price objective for the company.March 12, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Hits New 12-Month Low - Time to Sell?Immunome (NASDAQ:IMNM) Reaches New 12-Month Low - Should You Sell?March 11, 2025 | marketbeat.comImmunome initiated with an Outperform at LifeSci CapitalMarch 11, 2025 | markets.businessinsider.comImmunome (NASDAQ:IMNM) Given Outperform Rating at WedbushWedbush reissued an "outperform" rating and set a $33.00 target price on shares of Immunome in a research note on Monday.March 11, 2025 | marketbeat.comImmunome doses first patient in IM-1021 trialMarch 10, 2025 | markets.businessinsider.comImmunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADCMarch 10, 2025 | businesswire.comImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 6, 2025 | businesswire.comLos Angeles Capital Management LLC Invests $379,000 in Immunome, Inc. (NASDAQ:IMNM)Los Angeles Capital Management LLC acquired a new stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 35,721 shares of the company's stock, valued at approximately $379,000. Los AngMarch 4, 2025 | marketbeat.comHandelsbanken Fonder AB Sells 30,000 Shares of Immunome, Inc. (NASDAQ:IMNM)Handelsbanken Fonder AB cut its holdings in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 13.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 200,000 shares of the company's stock after selling 30,000 sharFebruary 26, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Hits New 12-Month Low - Here's What HappenedImmunome (NASDAQ:IMNM) Hits New 1-Year Low - Here's WhyFebruary 25, 2025 | marketbeat.comImmunome to Present at Upcoming March ConferencesFebruary 25, 2025 | businesswire.comImmunome, Inc. (NASDAQ:IMNM) Sees Significant Drop in Short InterestImmunome, Inc. (NASDAQ:IMNM - Get Free Report) saw a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 9,070,000 shares, a drop of 13.9% from the January 15th total of 10,540,000 shares. Based on an average daily volume of 1,000,000 shares, the days-to-cover ratio is currently 9.1 days. Currently, 13.0% of the shares of the stock are sold short.February 17, 2025 | marketbeat.comThree Bridge Wealth Advisors LLC Buys New Position in Immunome, Inc. (NASDAQ:IMNM)Three Bridge Wealth Advisors LLC purchased a new stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 27,615 shares of the company's stock, valued at approximately $293,000. OtherFebruary 13, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Stock Price Down 6.7% - Here's What HappenedImmunome (NASDAQ:IMNM) Stock Price Down 6.7% - Here's WhyFebruary 11, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Stock Price Up 11.7% - Here's What HappenedImmunome (NASDAQ:IMNM) Shares Up 11.7% - Still a Buy?February 10, 2025 | marketbeat.comQ1 Earnings Forecast for Immunome Issued By Leerink PartnrsImmunome, Inc. (NASDAQ:IMNM - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Immunome in a report released on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings per share of ($0.94) for the quarFebruary 10, 2025 | marketbeat.comImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 6, 2025 | businesswire.comInsider Stock Buying Reaches US$2.82m On ImmunomeFebruary 4, 2025 | uk.finance.yahoo.comImmunome (NASDAQ:IMNM) Shares Gap Up After Insider Buying ActivityImmunome (NASDAQ:IMNM) Shares Gap Up After Insider Buying ActivityFebruary 4, 2025 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) CEO Purchases $1,162,500.00 in StockFebruary 4, 2025 | insidertrades.comShort Interest in Immunome, Inc. (NASDAQ:IMNM) Grows By 12.2%Immunome, Inc. (NASDAQ:IMNM - Get Free Report) was the target of a significant growth in short interest in January. As of January 15th, there was short interest totalling 9,870,000 shares, a growth of 12.2% from the December 31st total of 8,800,000 shares. Approximately 19.2% of the shares of the company are sold short. Based on an average daily volume of 787,000 shares, the short-interest ratio is presently 12.5 days.February 4, 2025 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall Buys 150,000 SharesImmunome, Inc. (NASDAQ:IMNM - Get Free Report) CEO Clay B. Siegall purchased 150,000 shares of the firm's stock in a transaction dated Friday, January 31st. The stock was purchased at an average cost of $7.75 per share, for a total transaction of $1,162,500.00. Following the acquisition, the chief executive officer now owns 669,636 shares of the company's stock, valued at approximately $5,189,679. This trade represents a 28.87 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.February 3, 2025 | marketbeat.comScharf Investments LLC Makes New Investment in Immunome, Inc. (NASDAQ:IMNM)Scharf Investments LLC purchased a new stake in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 44,389 shares of the company's stock, valued aFebruary 1, 2025 | marketbeat.comImmunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesJanuary 31, 2025 | finance.yahoo.comImmunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesJanuary 31, 2025 | businesswire.com Remove Ads Get Immunome News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter. Email Address IMNM Media Mentions By Week IMNM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMNM News Sentiment▼-0.230.62▲Average Medical News Sentiment IMNM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMNM Articles This Week▼234▲IMNM Articles Average Week Remove Ads Get Immunome News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MLTX News Today IBRX News Today BEAM News Today VCEL News Today MIRM News Today EWTX News Today CNTA News Today KYMR News Today CGON News Today DNLI News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMNM) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMNM Stock Free IMNM Stock Alerts